2016 Grants & Awards

GRANTS-IN-AID OF RESEARCH

The Crohn’s and Colitis Canada Grants-in-Aid of Research program supports research on inflammatory bowel disease (IBD). This research program helps advance prevention, treatments, health policy and, ultimately find cures. Grants support research projects with a defined objective, conducted by an investigator working alone or in collaboration with others. Grants are awarded for a maximum of three years, at maximum $125,000 per annum.

Dr. Laura Targownik

 Co-Investigators: Dr. Eric Benchimol, Dr. Geoff Nguyen, Dr. Lisa Lix, Dr. Sanjay Murthy, Dr. Kevan Jacobson, Dr. Gregory Rosenfeld, Dr. Cynthia Seow, Dr. Gilaad Kaplan, Dr. Jennifer Jones, Dr. Juan Nicholas Pena-Sanchez, Dr. Charles Bernstein, Dr. Harminder Singh, Dr. Alain Bitton, Dr. Maria Vutcovici, Dr. Murray Krahn

Linking Population Based Provincial Health Care Utilization Databases to Evaluate Drug Related Outcomes in IBD

University of Manitoba

Dr. Targownik is using provincial health records to see how medications for IBD are being used by Canadians. This work will help healthcare professionals determine whether early use of biologics and/or combination therapy are beneficial to patients

$350,740

(2016-2019)

Dr. Stephen Vanner 

Co-Investigators: Dr. Katrina Gee, Dr. David Reed, Dr. Alan Lomax

Turning off the ‘Switch’: Preserving the Analgesic Actions of the Endogenous Opioid Pathway in IBD 

 

Queen’s University

Pain is a debilitating symptom for many with IBD. Dr. Vanner is studying how the abdominal pain seen in IBD is caused and whether there are more effective ways to treat it. Ultimately, this work may lead to better management of pain medications.

$355,000

(2016-2019)

Dr. Stuart Turvey

Development of Anti-Inflammatory Nanomedicine for Inflammatory Bowel Disease

University of British Columbia

Dr. Turvey is attaching tiny gold nanoparticles to peptides to reduce inflammation. He’s had positive results so far using this therapy to improve the health IBD mice and will now launch larger scale studies to confirm the benefits. Ultimately, this research will facilitate the development of new nanomedicines to treat people living with IBD.

$355,000

(2016-2019)

Dr. Bruce Vallance 

 

Co-Investigator: Dr. Leigh Knodler

Intestinal Epithelial Inflammasomes: Frontline Defenders against IBD? 

University of British Columbia

Dr. Vallance is studying immune cells involved in protecting gut tissue from foreign bacteria. He is looking at ways of improving these cells’ abilities to control inflammation and promote gut healing in IBD.

$355,000

(2016-2019)

Dr. Theodore Steiner 

Co-Investigator: Dr. Megan Levings

Development of Regulatory T cell immunotherapy for IBD 

University of British Columbia

Dr. Steiner is looking to enhance the ability of a white blood cell (regulatory T cells) to keep inflammation in check. They will collect these cells from human volunteers and improve function to find the best method to scale up and develop a therapy for IBD patients.

$355,000

(2016-2019)

Dr. Elena Verdu

The role of Microbial Proteases in Colitis

McMaster University

Dr. Verdu will be investigating the impact that bacteria collected from UC patients has on germ-free mice in order to better understand how the certain bacteria may lead to gut leakiness or chronic inflammation seen in IBD

$355,000

(2016-2019)

Dr. Claude Asselin

Histone deacetylases: epigenetic regulators of intestinal epithelial homeostasis

Université Sherbrooke

Our body responds to the environment which can make us more or less susceptible to disease. The environment can cause a gene to turn “on” or “off” through epigenetic changes. Dr. Asselin is studying how certain proteins control genetic and epigenetic information in the gut cells leading to IBD

$355,000

(2016-2019)
 

INNOVATIONS IN IBD GRANTS

Crohn's and Colitis Canada invites applications for an "Innovations Grant", to fund novel or innovative approaches to IBD research. This grant is intended to stimulate and support research which may not be encompassed within the boundaries of traditional medical research. This is a 1 year, $50,000 grant.

Dr. Martin Pelletier

Characterizing the role of inflammatory cells' bioenergetics in the pathophysiology of colitis 

Universite Laval

This study aims at characterizing different parameters of energy metabolism in immune cells during disease progression in a mouse model of colitis. This research could enable the development of improved biomarkers for inflammatory bowel disease based on immune cell’s energy metabolism and thus improve the diagnosis or pave the way for new treatments of inflammatory disorders.

$50,000

(2016-2017)

Dr. Jane Shearer

Use of a Mitochondrial Fission Inhibitor as a treatment of Inflammatory Bowel Disease  

University of Calgary

This innovation grant seeks to understand the relationship between mitochondrial fission, intestinal barrier function and IBD. It will build upon preliminary data showing that targeting mitochondrial fission through a novel peptide inhibitor (P110) may be of therapeutic benefit in IBD. This peptide has been shown to be effective in other disease states where oxidative stress, cell death and fission are implicated.

$50,000

(2016-2017)

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 150 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest